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Abstract: Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of 
blindness in the working-aged population of most developed countries. The increasing number 
of persons with diabetes worldwide suggests that DR/DME will continue to be major contribu-
tors to vision loss and associated functional impairment for years to come. Early detection of 
retinopathy in persons with diabetes is critical in preventing visual loss, but current methods of 
screening fail to identify a sizable number of high-risk patients. The control of diabetes-asso-
ciated metabolic abnormalities (ie, hyperglycemia, hyperlipidemia, and hypertension) is also 
important in preserving visual function, as these conditions have been identiﬁ  ed as risk factors 
for both the development and progression of DR/DME. The non-pharmacologic interventions for 
DR/DME, laser photocoagulation and vitrectomy, only target advanced stages of disease. Several 
biochemical mechanisms, including increased vascular endothelial growth factor production, 
protein kinase C β activation, oxidative stress, and accumulation of intracellular sorbitol and 
advanced glycosylation end products, may contribute to the vascular disruptions that characterize 
DR/DME. The inhibition of these pathways holds the promise of the intervention for diabetic 
retinopathy with higher success rate and also at earlier, non-sight-threatening stages.
Recent pathophysiologic insights
Diabetic retinopathy/diabetic macular edema (DR/DME) are common microvascular 
complications in patients with diabetes, and may have a sudden, and debilitating impact 
on visual acuity (VA), eventually leading to blindness. DR is characterized by the growth 
of abnormal retinal blood vessels secondary to ischemia. These blood vessels grow in an 
attempt to supply oxygenated blood to the hypoxic retina. At any time during the progres-
sion of DR, patients with diabetes mellitus can also develop DME, which involves retinal 
thickening in the macular area. DME occurs following breakdown of the blood–retinal 
barrier due to leakage of dilated, hyperpermeable capillaries and microaneurysms. The 
current management strategy for DR/DME requires early detection and optimal metabolic 
control to slow the progression of disease. Adherence to these recommendations is ham-
pered by the fact that the condition is generally asymptomatic at early stages. The non-
pharmacological treatments for DR/DME, laser photocoagulation and vitrectomy, only 
target advanced stages of DR/DME. Several pharmacologic therapies, mainly intravitreal 
triamcinolone and more recently anti vascular growth factor agents are currently used as 
an adjunctive therapy for DR/DME. Other pharmacologic therapies are developed to treat 
DR/DME. This review will focus on the current understanding of the pathophysiology of 
DR/DME and its present and potential future pharmacologic treatments.
DR/DME pathophysiology
Many studies have demonstrated that chronic hyperglycemia, as well as hypertension, and 
probably hyperlipidemia, contribute to the pathogenesis of DR (Klein et al 1988, 1991; 
The Diabetes Control and Complications Trial Research Group 1993; Chew et al 1996; 
Chaturvedi et al 1998; UK Prospective Diabetes Study Group 1998a, 1998b, 1998c). Clinical Ophthalmology 2007:1(4) 384
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The exact mechanisms by which elevated glucose initiates 
the vascular disruption in retinopathy remain poorly deﬁ  ned. 
Different biochemical mechanisms have been suggested as 
explanations for the development and progression of diabetic 
retinopathy and have led to exploration of possible treatments 
(Table 1).
The vascular disruptions of DR/DME are characterized by 
abnormal vascular ﬂ  ow, disruptions in permeability, and/or   
nonperfusion of capillaries. A hallmark of early DR is the change 
in the structure and cellular composition of the microvasculature 
(Kubawara and Cogan 1962; Sims 1986; Antonelli-Orlidge et al 
1989). Endothelial cells are responsible for maintaining the 
blood-retinal barrier, and damage to them results in increased 
vascular permeability. In early stages of DME, breakdown of the 
inner blood-retinal barrier occurs, resulting in accumulation of 
extracellular ﬂ  uid in the macula (Ferris and Patz 1984; Antcliff 
and Marshall 1999). Abnormal vessel permeability results in 
leakage of water, blood cells, proteins, and lipoproteins into the 
surrounding retinal tissue, and subsequent dysfunction of the 
macula resulting in decreased vision.
Pericytes are essential cellular components in the regulation 
of retinal capillary perfusion, and damage to these cells in dia-
betes mellitus leads to altered retinal hemodynamics, including 
abnormal autoregulation of retinal blood ﬂ  ow (Ciulla et al 2002). 
Loss of retinal pericytes represents another early feature of DR 
(Speiser et al 1968; Ansari et al 1998; Paget et al 1998), and 
correlates with microaneurysm formation (Cogan et al 1961; 
Kubawara and Cogan 1962; Speiser et al 1968).
There is evidence that retinal leukostasis may also play an 
important role in the pathogenesis of DR. Leukocytes possess 
large cell volume, high cytoplasmic rigidity, a natural ten-
dency to adhere to the vascular endothelium, and a capacity 
to generate toxic superoxide radicals and proteolytic enzymes 
(Miyamoto and Ogura 1999). In diabetes, there is increased 
retinal leukostasis that affects retinal endothelial function, 
retinal perfusion, angiogenesis, and vascular permeability. 
In particular, leukocytes in diabetes are less deformable, a 
higher proportion are activated and they may be involved 
in capillary non-perfusion, endothelial cell damage, and 
vascular leakage in the retinal microcirculation (Miyamoto 
and Ogura 1999). Streptozotocin-induced diabetic rats 
showed that diabetic vascular leakage and nonperfusion are 
temporally and spatially associated with retinal leukostasis 
(Miyamoto et al 1999). Serial acridine orange leukocyte 
ﬂ  uorography and ﬂ  uorescein angiography (FA) show trapped 
leukocytes directly associated with areas of downstream non-
perfusion in the diabetic retinal microcirculation (Miyamoto 
and Ogura 1999). While leukostasis probably plays a key role 
in the pathogenesis of DR, platelets and red blood cells are 
also involved in this process.
As a result of occluded capillaries, retinal ischemia stimu-
lates a pathologic neovascularization mediated by angiogenic 
factors, such as vascular endothelial growth factor (VEGF), 
which results in proliferative DR (PDR) (Aiello et al 1994, 
2001; Miller et al 1997). This neovascularization is the pre-
dominant feature of PDR. VEGF also plays an important role 
in the development of DME (Nguyen et al 2006). Another 
common feature of DR is the thickening of the capillary base-
ment membrane and increased deposition of extracellular 
matrix components. This may contribute to the development 
of abnormal retinal hemodynamics (Williamson and Kilo 
1984), including abnormal autoregulation of retinal blood 
ﬂ  ow. Understanding the diabetes-induced mechanisms that 
contribute to pericyte loss, endothelial cell proliferation, 
neovascularization, and alterations in basement membrane 
structure is therefore central to the design of pharmacologic 
therapeutic strategies to treat and prevent early diabetes-related 
microvascular changes.
DR/DME management
and treatment
Control of systemic metabolic 
abnormalities
Control of the metabolic abnormalities of diabetes has a major 
effect on the development of diabetic microvascular compli-
cations (Aiello and Cahill 2001). The DCCT and the United 
Table 1 DR/DME proposed mechanism and currently/near 
future available corresponding therapy
Mechanism Mechanism-related  therapy
Elevated VEGF  Anti VEGF
   •  Ranibizumab (Lucentis)
   •  Bevacizumab (Avastin)
   •  Pegaptanib (Macugen)
Relative/absolute  PEDF gene – early
insufﬁ  ciency of PEDF  stages of research
Inﬂ  ammation  Intravitreal Steroids
   •  Triamcinolone (Kenalog)
        effective but with side effects
   •  Dexamethasone (Posurdex) – in
      Phase  III  trial
   •  Fluocinolone acetonide implant 
        (Retisert) – at present, proven for uveitis
      only
Activation of PKC  PKC β Inhibitor
   •  Ruboxistaurin (Arxxant) – proven in
        Phase III trial, under FDA review
Genetics  None at present
Abbreviations: VEGF, vascular endothelial growth factor; PEDF, pigment 
epithelium-derived factor; PKC, protein kinase C.Clinical Ophthalmology 2007:1(4) 385
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Kingdom Prospective Diabetes Study (UKPDS) showed that 
optimal metabolic control could reduce the incidence and 
progression of DR (The Diabetes Control and Complications 
Trial Research Group 1993; UK Prospective Diabetes Study 
Group 1998a). The beneﬁ  ts of intensive glycemic control per-
sisted over an extended follow up (Diabetes Control and Com-
plications Trial 2000). Thus, optimal metabolic control should be 
an important treatment goal and should be implemented early and 
maintained for as long as it is safely possible (Diabetes Control 
and Complications Trial 2000). Rigid control of hypertension is 
also effective in reducing disease progression (Chaturvedi et al 
1998; UK Prospective Diabetes Study Group 1998b, 1998c). 
Hyperlipidemia has been linked to the presence of retinal hard 
exudates in patients with DR (Klein et al 1991; Chew et al 1996). 
The Early Treatment Diabetic Retinopathy Study (ETDRS) 
(Chew et al 1996) had indirectly found that elevated cholesterol 
resulted in doubling the risk of retinal hard exudates at baseline, 
increasing the risks of developing hard exudates during follow-up 
and moderate vision loss at 5 years by 50%, each. Also, some 
evidence suggests that lipid-lowering therapy may reduce hard 
exudates and microaneurysms (Gordon et al 1991). The Action 
to Control Cardiovascular Risk in Diabetes (ACCORD), a ran-
domized, multicenter trial involving 10,000 patients with type 
2 diabetes mellitus patients is currently being conducted in the 
US (NIH News Release 2003). Around 4000 patients within the 
ACCORD trial participate in an ophthalmic sub-study, which 
should directly assess the role of cholesterol control and other 
metabolic parameters in preventing and slowing the progression 
of DR/DME. ACCORD trial results are expected in 2010.
The following are the recommended values for hemoglobin 
A1c (HbA1c < 6.5%–7%), blood pressure (<130/<85 mm Hg), 
and low-density lipoprotein (LDL) cholesterol Assoc. of 
Clinical Endocrinologists 2000; Hutchinson et al 2000). 
However, many patients fail to achieve or maintain these 
levels of metabolic control. In patients who do achieve a 
signiﬁ  cant reduction in HbA1c, there is an associated increased 
risk of severe hypoglycemia (The Diabetes Control and 
Complications Trial Research Group 1993; UK Prospective 
Diabetes Study Group 1998a; Chase et al 2001). Primary 
care physicians need to recognize correctable risk factors 
(ie, hyperglycemia, hypertension, and/or hyperlipidemia) so 
that appropriate monitoring and referral for eye care can be 
implemented.
DR/DME non-pharmacologic 
therapies
Laser photocoagulation therapy has proven effective in 
reducing DR progression, and vitrectomy can in many cases 
prevent severe vision loss in patients with advanced stages of 
DR. Unfortunately, both treatments carry a risk of additional 
vision loss, and neither is effective at restoring the vision 
to normal. Laser photocoagulation is used to treat both DR 
and DME. The goal of macular laser photocoagulation for 
DME is to limit vascular leakage through a series of focal 
laser burns at leaking microaneurysms or grid laser burns 
in regions of diffuse breakdown of the blood-retinal barrier 
and macular areas with capillary non-perfusion. The ratio-
nale of focal/grid laser treatment is to reduce the leakage 
from the microaneurysms and hence reducing the macular 
edema, reduce the macular area in the inner retina which is 
ischemic and hypoxic, and perhaps to allow oxygen from the 
choriocapillaris to diffuse to the hypoxic inner retina near 
it. The rationale of panretinal photocoagulation for PDR is 
to ablate ischemic areas of the peripheral retina and thereby 
reduce the induction of angiogenic growth factors. Results 
of the Diabetic Retinopathy Study (DRS) demonstrated that 
panretinal photocoagulation effectively reduces the risk of 
vision loss in a majority (60%) of patients with PDR (Ferris 
1993). The Early Treatment Diabetic Retinopathy Study 
(ETDRS) compared outcomes in eyes assigned to either 
deferral of macular laser photocoagulation or immedi-
ate treatment for clinically-signiﬁ  cant DME, [deﬁ  ned as; 
retinal edema within 500 μm of the center of the fovea; 
hard exudates within 500 μm of the fovea, if associated 
with adjacent retinal thickening (which may be outside the 
500 μm limit); retinal edema that is one disc area (1500 μm) 
or larger, any part of which is within one disc diameter or the 
center of the fovea] (Early Treatment Diabetic Retinopathy 
Study Research Group 1985). ETDRS results showed that 
macular laser photocoagulation reduced the risk of vision 
loss by 50% for patients with clinically-signiﬁ  cant DME. 
Macular focal and grid laser photocoagulation is indicated 
for clinically-signiﬁ  cant DME, and panretinal photocoagula-
tion is indicated for high-risk PDR (Mogensen et al 1979; 
Early Treatment Diabetic Retinopathy Study Research 
Group 1985; Raskin and Arauz-Pacheco 1992; Ferris 
1993). In more severe cases of DR, speciﬁ  cally those with 
tractional retinal detachment or severe non-clearing vitreous 
hemorrhage, vitrectomy is indicated to prevent blindness 
and/or severe visual loss (Mason et al 2006). Vitrectomy 
is clearly beneﬁ  cial for the treatment of advanced, active 
PDR (Diabetic Retinopathy Vitrectomy Study Research 
Group 1988). Early vitrectomy increased the percentage 
of eyes with a VA of ≥ 10/20 or better to 44%, compared 
with 28% in a conventionally managed group (Diabetic 
Retinopathy Vitrectomy Study (DRVS) Research Group Clinical Ophthalmology 2007:1(4) 386
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1988). The use of early vitrectomy is also warranted for eyes 
with very severe PDR, but not for patients with less severe 
DR (DRVS Research Group 1988; DRVS Research Group 
1990). However, recent advances in surgical techniques and 
technology since the DRVS have led to enhancement of the 
risk/beneﬁ  t ratio for pars plana vitrectomy and widening 
indications for this procedure (Mason et al 2006). Vitrec-
tomy may be of beneﬁ  t in the management of DME. An 
ongoing study by the Diabetic Retinopathy Clinical Research 
Network, is currently evaluating the role of focal/grid laser 
compared with vitrectomy for DME (Mason et al 2006). A 
recently published paper compared the effects of PPV and 
dye-enhanced ILM peel with grid laser in diffuse DME 
(Kumar et al 2006). Kumar et al study involved 24 eyes of 24 
patients with metabolically stable diabetes and with diffuse 
DME, and found that at the end of 6 months follow-up, the 
foveal thickness and macular volume have decreased more 
signiﬁ  cantly in the PPV/ILM group compared to the laser 
group (p = 0.001), without any signiﬁ  cant beneﬁ  t to the 
visual acuity (p = 0.525). In this study (Kumar et al 2006), 
no correlation was found between the improvement in visual 
acuity and the reduction of foveal thickness.
Given the risk of blindness without treatment, laser 
photocoagulation and/or vitrectomy will continue to have 
a major role in the management of DR/DME. Both laser 
photocoagulation and vitrectomy improve quality of life for 
patients with DR and are cost-effective (Javitt et al 1989; 
Sharma et al 2000; Sharma et al 2001). However, these 
interventions are indicated only when DR has progressed to 
a measurably advanced stage in which some visual acuity 
may already be lost. Side effects, such as loss of peripheral, 
night, or color vision, are noted by some photocoagulation-
treated patients (Early Treatment Diabetic Retinopathy 
Study Research Group 1991b). Vitrectomy can accelerate 
cataract formation and includes risks of retinal detachment 
and endophthalmitis, which are fortunately rare (Lewis et al 
1992). In some patients treated with photocoagulation, DR 
continues to progress and ongoing treatment is necessary. 
DME can also reoccur. These limitations, together with the 
growing numbers of diabetics worldwide, have led the phar-
maceutical industry to invest in the study of pharmacologic 
therapies for DR/DME.
Current and potential near future 
DR/DME pharmacologic therapies
Due to the limitations of non-pharmacologic DR/DME treat-
ments, the use of current available pharmacological therapies 
is increasing, while other pharmacologic agents, targeting the 
underlying biochemical DR/DME mechanisms that cause 
DR/DME are being developed.
Role of steroids for diabetic 
macular edema
Corticosteroids are known to reduce vascular permeability, 
reduce blood-retinal barrier breakdown, downregulate VEGF 
production, and inhibit certain matrix metalloproteinases. 
(Bhavsar 2006) There are several steroids that are being 
investigated for the treatment of diabetic retinopathy and 
its complications.
Triamcinolone acetonide (Kenalog®)
Intravitreal injections of triamcinolone acetonide (IVTA) 
are mostely given at a dose of 4 mg/0.1 ml but may be given 
at a higher dose of 20–25 mg/0.2 ml, as given by Jonas et al 
Over the last several years are gaining popularity by oph-
thalmologists around the world, as an adjunctive therapy to 
DME. The major complications of IVTA include elevated 
intraocular pressure in approximately 30%–50% of patients, 
cataract, and less commonly severe inﬂ  ammatory response, 
and endophthalmitis (Bhavsar 2006). Since no pharmaceuti-
cal company support the study of commercially available 
triamcinolone acetonide, nearly all the publications in this 
topic are on relatively small and uncontrolled studies. An 
exception is Gillis et al recently published prospective, 
double-masked, placebo-controlled, randomized clinical trial 
on the 2-year safety and efﬁ  cacy outcomes of intravitreal 
triamcinolone injections (4 mg/0.1 ml) for DME (Gillies et al 
2006). Sixty-nine eyes of 43 patients with impaired vision 
that persisted or recurred after laser treatment entered into 
the study. Thirty four eyes randomized to receive active treat-
ment and 35 placebo. Two-year data were available for 60 of 
69 (87%) eyes of 35 of 41 (85%) patients. Eyes randomized 
to placebo received a subconjunctival injection of saline. 
Improvement of > or = 5 letters’ best-corrected visual acuity 
was found in 19 of 34 (56%) eyes treated with intravitreal 
triamcinolone compared with 9 of 35 (26%) eyes treated with 
the placebo (p = 0.006). The mean improvement in VA was 
5.7 letters more in the triamcinolone-treated eyes than in those 
treated with the placebo. An increase of intraocular pressure 
(IOP) of > or = 5 mmHg was observed in 23 of 34 (68%) 
treated versus 3 of 30 (10%) untreated eyes (p < 0.0001). 
Glaucoma medication was required in 15 of 34 (44%) treated 
versus 1 of 30 (3%) untreated eyes (p = 0.0002). Cataract sur-
gery was performed in 15 of 28 (54%) treated versus 0 of 21 
(0%) untreated eyes (p < 0.0001). Two eyes in the intravitreal 
triamcinolone-treated group required trabeculectomy. Clinical Ophthalmology 2007:1(4) 387
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Also, there was one case of infectious endophthalmitis in 
the treatment group.
Due to concerns regarding the possible toxic effects of 
the preservatives (mainly from the benzyl alcohol) within the 
commercially available triamcinolone acetonide (Kenalog®), 
Allergan has developed a preservative free triamcinolone 
acetonide, which is used now by the Diabetic Retinopathy 
Clinical Research Network for DME and also by the National 
Eye Institute in cases of retinal vein occlusion (SCORE trial). 
However, a recent human study, in which 4 mg of Kenalog 
was given intravitreally to DME, refractory to grid laser, did 
not ﬁ  nd electroretinographic evidence of a retinotoxic effect 
of commercially avaliable Kenalog (Lang et al 2007).
Dexamethasone: Posurdex
The dexamethasone implant, Posurdex (Allergan Pharma-
ceuticals, Irvine, CA), is a biodegradable copolymer of poly 
[lactic-glycolic] acid and is designed for intravitreal delivery 
of dexamethasone for approximately 6 months (pers. comm., 
unpublished). A Phase II multicenter, controlled trial in 
patients with persistent macular edema due to a variety of 
causes including diabetic retinopathy, retinal vein occlusions, 
pseudophakic CME, and uveitis randomized 306 patients 
1:1:1 to Posurdex 350 μg, Posurdex 750 μg, or observation 
(Diabetic Retinopathy 2006). Within this study, there were 
172 patients with DME. In this subset of patients, there was 
a statistically signiﬁ  cant beneﬁ  t of reduction of ﬂ  uorescein 
angiographic leakage at day 90 and reduction of retinal 
thickness with both the 350 μg, and 700 μg, implants. With 
respect to safety at day 180 in the DME subset, 4.1% (350 μg) 
and 6.1% (700 μg) of eyes had an intraocular pressure of 
25 mmHg compared with 0.0% of eyes in the observation 
group. The presence or absence of cataract was similar 
among all groups.
Phase III clinical trials for DME (as well as for retinal vein 
occlusion) are currently being conducted, in which Posurdex 
is being injected intravitreally using a single use applicator.
Fluocinolone acetonide 
implant (Retisert)
The ﬂ  uocinolone acetonide implant Retisert (Control Deliv-
ery Systems and Bausch and Lomb, Rochester, NY) is still 
being investigated for decreasing diabetic macular edema. 
This implant, approximately 2X2X6 mm in size, is designed 
to provide sustained release of ﬂ  uocinolone for 1,000 days. 
The implant is inserted in the operating room through a 
pars plana incision and is sutured to the sclera, similar 
to the insertion of the ganciclovir implant. In a Phase III 
multicenter, masked, controlled, safety and efﬁ  cacy study, 
80 patients were randomized to either the 0.5 mg implant or 
the 2 mg implant versus standard of care (SOC), macular 
grid laser or observation (Pearson et al 2004). At 24 months, 
the 0.5 mg implant of ﬂ  uocinolone showed resolution of 
macular edema in 53.7% of eyes versus 28.6% of the SOC 
eyes; 2 grade reduction in retinal thickness at the center of 
the macula in 46.2% of eyes versus 14.8% of SOC eyes; and 
a trend toward stabilizing or improving diabetic retinopathy 
scores in 87.2% of eyes versus 62.9% in SOC eyes. The 
major serious adverse events included elevation of intraocular 
pressure in 31.7% of the 0.5 mg group versus none of the 
standard of care group, with 19.5% of patients in the 0.5 mg 
group requiring trabeculectomy surgery and serious cataract 
progression and cataract extraction in 74.2% of eyes with the 
0.5 mg group compared with 13.3% of eyes in the standard 
of care group (Bhavsar 2006).
Role of angiogenic factors and use
of anti-angiogenic agents
The VEGFs (vascular endothelial growth factors) are a 
family of peptides produced from a single gene by alterna-
tive splicing (Frank 2004). VEGF isoforms are speciﬁ  cally 
mitogenic for vascular endothelial cells and also increase 
permeability at blood–tissue barriers. VEGF is essential for 
the formation of the fetal vascular system and its expression 
decreases substantially after birth. Some cells, however, 
constitutively secrete picomolar amounts; cells in the neural 
retina secrete 15–20 pg per milligram of protein, and cells in 
the combined choroid and retinal pigment epithelium secrete 
50 pg per milligram of protein. Constitutive VEGF secretion 
from the retinal pigment epithelium is asymmetric, occur-
ring primarily from the basal surface of these cells. VEGF 
expression is enhanced by hypoxia, which is a major stimulus 
for retinal neovascularization. Reduced retinal blood ﬂ  ow 
and accompanying hypoxia may be present even before the 
early signs of retinopathy, such as loss of capillary pericytes 
and endothelial cells, are identiﬁ  ed, and these changes are 
likely to be accompanied by an increase in the synthesis 
and secretion of VEGF. Increased VEGF protein has been 
demonstrated in nonvascular cells in the eyes of persons with 
diabetes even in the absence of retinopathy supporting the 
hypothesis that diabetic retinopathy begins as a disease of 
retinal neurons and glia and only later involves the retinal 
vasculature. (Frank 2004).
Clinical studies have shown that VEGF levels increase 
in patients as they progress from nonproliferative DR to 
active PDR (Aiello et al 1994; Miller et al 1997). Successful Clinical Ophthalmology 2007:1(4) 388
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panretinal photocoagulation has been found to reduce 
intraocular VEGF levels by 75% (p = 0.008) in patients 
treated for ocular neovascularization (Aiello et al 1994). This 
has led to the use of anti VEGFs in DR/DME. There are at 
present three major anti VEGFs which are being used for 
DR/DME. Two anti VEGFs are in advanced clinical trials: 
pegaptanib sodium, Macugen (Eyetech, New York, NY), and 
ranibizumab, Lucentis (Genentech, San Francisco, CA). The 
third, bevacizumab (Avastin), is widely used since 2006 as an 
off-labeled indication for different retinal diseases, mainly, 
wet age-related macular degeneration, but more recently for 
other retinal diseases, including DR/DME.
Pegaptanib is an aptamer that binds to the VEGF165 
isoform of the VEGF-A gene. The Phase II DME trial of 
pegaptanib randomized 169 patients to one of three doses of 
intravitreal pegaptanib, 0.3 mg, 1 mg, or 3 mg versus standard 
of care with injections every 6 weeks for 12 weeks, with 
continued injections at the discretion of the investigators for 
up to 30 weeks. Thermal laser was permitted after 12 weeks 
(Macugen Diabetic Retinopathy Study Group 2005). The 
eyes that were treated with the 0.3 mg dose had a statistically 
signiﬁ  cant gain in BCVA of 0 to 3 lines compared with the 
usual care eyes (73% versus 51%). Initial safety data show 
that pegaptanib appears to be well tolerated. The same study 
found Pegaptanib to cause either a temporary regression of 
neovascularization on fundus photographs or regression 
or absence of ﬂ  uorescein leakage from neovascularization 
(Macugen Diabetic Retinopathy Study Group).
Ranibizumab is an afﬁ  nity matured antibody fragment 
that binds to all of the isoforms of VEGF produced by the 
VEGF-A gene. Ranibizumab is currently being investigated 
in the treatment of diabetic macular edema in Phase II clini-
cal studies. Recently, an open-label study to investigate the 
effect of intravitreal injections of 0.5 mg of ranibizumab in 
10 patients with DME was published by Nguyen et al (2006). 
Ranibizumab was intravitreally injected at study entry and 
at one, two, four, and six months after entry. Mean values 
at baseline were 503 μm for foveal thickness and 28.1 let-
ters (20/80) read on an ETDRS visual acuity chart. At seven 
months (one month after the ﬁ  fth injection), the mean foveal 
thickness was 257 μm (a reduction of 246 μm; p = 0.005) and 
the mean visual acuity was 40.4 letters (20/40), which was 
an improvement of 12.3 letters (p = 0.005). Also, the injec-
tions were well-tolerated with no ocular or systemic adverse 
events.
Another ranibizumab/DME study, by Chun et al has 
recently been published (Chun et al 2006). This was a 
single-center, open-label, dose-escalating pilot study, with a 
total of 10 eyes of 10 patients. Three intravitreal injections of 
ranibizumab (0.3 mg or 0.5 mg, 5 patients each) administered 
on day 0, month 1, and month 2, and observation until month 
24. At month 3, 4 of 10 patients gained > or = 15 letters, 5 
of 10 gained > or = 10 letters, and 8 of 10 gained > or = 1 
letters. At month 3, the mean decrease in retinal thickness of 
the center point of the central subﬁ  eld was 45.3 +/− 196.3 μm 
for the low-dose group and 197.8 +/− 85.9 μm for the high-
dose group. Also, intravitreal ranibizumab was well tolerated 
and no systemic adverse events were reported.
The efﬁ  cacy of intraviteal injections of 1.25 mg beva-
cizumab (Avastin; Genentech) for the treatment of diabetic 
macular edema was recently tested in prospective, con-
secutive, noncomparative case series included 51 diabetic 
patients.   (Haritoglou et al 2006). All patients completed 6 
weeks of follow-up and 23 (45%) completed 12 weeks of 
follow-up. Sixteen patients (70%) had received at least two 
intravitreal injections. All patients had undergone previous 
treatments, such as focal laser therapy (35%), full-scatter 
panretinal laser therapy (37%), vitrectomy (12%), and intra-
vitreal injection of triamcinolone (33%). The mean diameter 
of the foveal avascular zone was 503 μm, with 49% with 
values of >500 μm. At baseline, mean visual acuity was 0.86 
+/− 0.38 logMAR of Snellen letters. Mean central retinal 
thickness by OCT was 501 +/− 163 μm. Mean visual acuity 
increased to 0.75 +/− 0.37 logMAR of Snellen letters at 6 
weeks after injection (p = 0.001), with some regression to 
0.84 +/− 0.41 logMAR of Snellen letters after 12 weeks. 
Mean retinal thickness +/− SD decreased to 425 +/− 180 
μm at 2 weeks (p = 0.002), 416 +/− 180 μm at 6 weeks 
(p = 0.001), and 377 +/− 117 μm at 12 weeks (p = 0.001). 
Changes of retinal thickness and visual acuity correlated 
weakly (r = −0.480 and p = 0.03 at 6 weeks; r = −0.462 and 
p = 0.07 at 12 weeks).
The effect of a single intravitreal 1.5 mg bevacizumab 
(Avastin) for persistent new vessels (NV) associated with 
proliferative diabetic retinopathy was recently tested in a pro-
spective, nonrandomized open-label study of diabetic patients 
with actively leaking NV refractory to laser treatment and 
best-corrected ETDRS visual acuity worse than 20/40 (Jorge 
et al 2006) . Fifteen consecutive patients were included and all 
completed the 12-week follow-up study period. The mean area 
of active leaking NV decreased signiﬁ  cantly from 27.79 +/− 
6.29 mm2 at baseline to 5.43 +/− 2.18 mm2 and 5.50 +/− 1.24 
mm2 (p < 0.05) at 1 and 12 weeks postinjection, respectively. 
At week 6 no leakage was observed. The mean visual acuity 
improved signiﬁ  cantly from 0.90 (20/160) +/− 0.11 at baseline 
to 0.76 (20/125(+2)) +/− 0.12, 0.77 (20/125(+2)) +/− 0.11, and Clinical Ophthalmology 2007:1(4) 389
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0.77 (20/125(+2)) +/− 0.12 at weeks 1, 6, and 12, respectively 
(p < 0.05). No major adverse events were observed.
Role of PKC β pathway and use of PKC 
β inhibitors
Experimental studies have shown that protein kinase C (PKC) 
activity and levels of diacylglycerol (DAG), an activator of 
PKC, are increased following exposure of vascular tissues 
to elevated glucose (Inoguchi et al 1992; Xia et al 1994). 
Diabetes-induced DAG may derive from hydrolysis of 
phosphatidylinositides, metabolism of phosphatidylcholine 
or de novo synthesis of phosphatidic acid (Koya and King 
1998). PKC activity is also increased following exposure of 
vascular endothelial cells to oxidative stress (Taher et al 1993; 
Nishikawa et al 2000a). PKC, β and δ have been identiﬁ  ed 
as the predominant isoforms activated in vascular tissues in 
response to hyperglycemia (Inoguchi et al 1992; Koya and 
King 1998). PKC β has been shown to have an important role 
in regulating endothelial cell permeability (Nagpala et al 1996) 
and is an important signaling component for VEGF (Xia et al 
1996). Transgenic animals overexpressing PKC β in vascular 
tissues developed retinal hemodynamic abnormalities similar 
to those observed in human DR (Takahara et al 1999).
The role of PKC in many cellular processes suggests 
that inhibition of all PKC isoforms would cause unac-
ceptable toxicity (Jirousek et al 1996; Arevalo et al 2007). 
Ruboxistaurin, a specific inhibitor of PKC β1 and β2, 
(Jirousek et al 1996) has been shown to prevent and reverse 
microvascular complications in animal models of diabetes 
(Ishii et al 1996), to block neovascularization associated with 
retinal ischemia (Danis et al 1998), and to inhibit the effect 
of VEGF on retinal permeability and endothelial cell growth 
(Aiello et al 1997).
The results of a Phase III, 36 months, randomized, 
double-masked, placebo-controlled, parallel, multicenter trial 
evaluating the effect of oral ruboxistaurin on vision loss in 
patients with diabetes was recently published (PKC-DRS2 
Group 2006). Six hundred eighty-ﬁ  ve patients randomized 
at 70 clinical sites and had ophthalmologic examination at 
screening and at each 3-month visit. Eligible patients had a 
best-corrected visual acuity (VA) score of > or = 45 letters, 
and no prior panretinal photocoagulation in at least one 
eye. The main outcome was the effect of oral ruboxistaurin 
(32 mg/day) on reduction of sustained moderate visual loss 
(> or = 15-letter decrease in ETDRS VA score maintained 
> or = 6 months) in patients with moderately severe to very 
severe nonproliferative diabetic retinopathy. It was shown 
that sustained moderate visual loss occurred in 9.1% of 
placebo-treated patients versus 5.5% of ruboxistaurin-treated 
patients (40% risk reduction, p = 0.034). When clinically 
signiﬁ  cant macular edema was >100 μm from the center of 
the macula at baseline, ruboxistaurin treatment was associ-
ated with less frequent progression of edema to within 100 
microm (68% vs 50%, p = 0.003). Also, initial laser treat-
ment for macular edema was 26% less frequent in eyes of 
ruboxistaurin-treated patients (p = 0.008).
Conclusions
Diabetic eye disease severely impacts quality of life for 
patients with diabetes by decreasing visual acuity and increas-
ing the risk of blindness. DR condition results in loss of 
capillary integrity, microaneurysm formation, and ischemia, 
which in turn drive the progression of PDR. Accumulation 
of ﬂ  uid in the retina secondary to capillary leakage and/or 
microaneurysms results in DME, which contributes to loss of 
vision in DR. There is substantial evidence that control over 
metabolic factors can effectively prevent the development 
and progression of DR/DME. However, many patients fail 
to achieve or maintain optimal levels of metabolic control. 
For such patients early detection and timely treatment of DR 
remains the standard of care. Although they are effective, 
sight-saving interventions, laser photocoagulation therapy 
and vitrectomy are invasive, associated with destructive 
side effects, and only treat the late stages of disease. In cases 
where laser insufﬁ  cient controls PDR/DME, we can now add 
pharmacologic therapies directly into the vitreous. Also, a 
number of pharmacological agents that could slow the pro-
gression of DR/DME in earlier stages are now being tested. 
The ﬁ  rst to be proven is the PKC inhibitor. These therapies 
have derived from improved understanding of the complex 
and often overlapping pathways involved in diabetes-induced 
microvascular damage. It is likely that in the future we would 
use a combination of pharmacological agents and at earlier 
stages of DR/DME. It is critical that healthcare providers 
interact with one another in managing patients to ensure that 
high-risk individuals are screened and treated early enough to 
beneﬁ  t from the progress in the DR/DME treatment modali-
ties and hence to better preserve vision.
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